ImpediMed specializes in medical technologies that use bioimpedance spectroscopy (BIS) to generate data for optimizing patient health. It produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for indications including lymphoedema, heart failure, and protein calorie malnutrition. The SOZO platform is sold in select markets globally. Led by Dr. Parmjot Bains, MD, CEO and Managing Director, the company intends to use the new proceeds to support continued execution of its commercial strategy. ImpediMed is based in Carlsbad, CA and was founded in Brisbane, Australia. The company recently raised $15M in growth funding.

Total raised

$15M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2025